AI for Clinical Documentation and Drug Labeling Automation

Pfizer is deploying AI across its clinical drug development pipeline to speed up the entire process from molecule to market. AI is being trained to predict drug efficacy and side effects, manage vast document workflows, and assist regulatory submissions. Machine learning analyzes terabytes of data at each development stage, spotting patterns that inform decisions. Pfizer uses AI to improve regulatory submissions by identifying likely regulator queries in advance and incorporating answers from the start, potentially saving weeks of back-and-forth. AI also helps decide which medications not to pursue—identifying drugs unlikely to be effective or with problematic side effects, allowing faster reallocation of resources. Pfizer generates hundreds of thousands of pages of reports and documentation for regulators annually, and AI automation handles much of this production. Natural language processing ensures correct and consistent terminology across documents while reducing errors. AI software trained by experts produces highly accurate labeling content for new drugs and updates it as information changes. Pfizer's AI systems scan thousands of external documents for relevant information, reducing the need for full human review of all literature. The company has deployed AI across its entire drug development lifecycle.